Home/NextCure/Kevin C. Deenihan

KC

Kevin C. Deenihan

Chief Financial Officer

Therapeutic Areas

Oncology Immunology

NextCure Pipeline

Drug	Indication	Phase
NC318	Non-small cell lung cancer (NSCLC), ovarian cancer, other solid tumors	Phase 1/2
NC410	Solid tumors (e.g., colorectal, ovarian, pancreatic)	Phase 1/2
NC525	Acute Myeloid Leukemia (AML)	Preclinical

Leadership Team at NextCure

Michael Richman

Former President and Chief Executive Officer

Solomon Langermann

Senior Vice President, Research & Development

Chief Operating Officer

Co-Founder and Scientific Advisor

Ellen R. Lubman

Chief Business Officer

View full NextCure profile